News

Article

FDA Publishes Guidance on Transdermal and Topical Delivery Systems

The guidance provides recommendations for the development and quality information that should be included in NDA and ANDA applications.

On Nov. 20, 2019, FDA published draft guidance recommending development and quality considerations for transdermal and topical delivery systems sponsors should include in new drug applications and abbreviated new drug applications.  Specifically, the guidance describes recommendations for product design and pharmaceutical development, manufacturing process and control, and finished product control. Areas where quality is closely tied to product performance and safety (e.g., adhesion failure and impacts of applied heat) are also addressed.

Source: FDA

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content